FDA OKs Clinical Trial Testing Cudetaxestat With Ofev, Esbriet

FDA OKs Clinical Trial Testing Cudetaxestat With Ofev, Esbriet

304270

FDA OKs Clinical Trial Testing Cudetaxestat With Ofev, Esbriet

The U.S. Food and Drug Administration (FDA) has authorized Blade Therapeutics to begin a Phase 1 clinical trial evaluating pharmacological interactions between its investigational medication, cudetaxestat (BLD-0409), and two approved treatments for idiopathic pulmonary fibrosis (IPF). The trial will enroll an estimated 86 healthy individuals, who will be given cudetaxestat alone, or in combination with either Ofev (nintedanib) or Esbriet (pirfenidone), both oral medications with FDA approval for IPF. The study’s main goal is to…

You must be logged in to read/download the full post.